A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung

Yu Wang1, Yan Tang1, Xiao-Mei Zhao1

  • 1Department of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University, Jiangsu Suzhou 215123, China.

Acta Biomaterialia
|September 26, 2022
PubMed

Insights

A novel non-viral vector effectively delivers CRISPR/Cas9 to cancer cells, disrupting the MTH1 gene to inhibit non-small cell lung cancer growth and metastasis.

Area of Science:

  • Biotechnology and Biomedical Engineering
  • Cancer Research and Therapeutics
  • Gene Editing Technologies

Background:

  • The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) system offers programmable genome editing with potential for long-lasting cancer treatment effects.
  • Efficient and safe delivery of CRISPR/Cas9 is crucial for its clinical application, with a need for advanced non-viral vectors.
  • Current non-viral vectors require enhancement for tumor cell targeting and nuclear delivery of CRISPR/Cas9 payloads.

Purpose of the Study:

  • To develop a multifunctional non-viral vector for efficient delivery of CRISPR/Cas9 plasmids into cancer cells.
  • To enable active targeting of tumor cells and facilitate nuclear delivery of the genome editing machinery.
  • To investigate the therapeutic potential of CRISPR/Cas9-mediated MTH1 gene disruption in non-small cell lung cancer (NSCLC).

Main Methods:

  • Construction of a multifunctional non-viral vector, PS@HA-Lip, incorporating protamine sulfate (PS) for DNA condensation and nuclear targeting, and liposomes coated with hyaluronic acid (HA) for active tumor cell targeting.
  • Encapsulation of CRISPR/Cas9 plasmids within the PS@HA-Lip vector to protect against nuclease degradation.
  • In vitro and in vivo evaluation of the vector's ability to deliver CRISPR/Cas9 into NSCLC cells, induce MTH1 gene editing, and assess therapeutic outcomes.

Main Results:

  • The PS@HA-Lip vector successfully delivered CRISPR/Cas9 plasmids into the nuclei of tumor cells, inducing genome editing.
  • Disruption of the MTH1 gene using CRISPR/Cas9 significantly inhibited non-small cell lung cancer growth.
  • Treatment promoted apoptosis in tumor tissues and reduced liver metastasis, demonstrating therapeutic efficacy and safety.

Conclusions:

  • A novel multifunctional non-viral vector (PS@HA-Lip) enables efficient CRISPR/Cas9 delivery and genome editing in NSCLC.
  • Targeting the MTH1 gene with CRISPR/Cas9 represents a promising therapeutic strategy for non-small cell lung cancer.
  • This study provides a viable non-viral delivery system for CRISPR/Cas9, advancing its application in cancer therapy.